NVX New Logo.PNG
NOVONIX Announces Participation in Upcoming Investor Events
February 25, 2024 17:59 ET | Novonix Ltd.
BRISBANE, Australia, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX”), a leading battery materials and technology company, today announced that members of the...
Figure 1
5E Advanced Materials Advances Closer to Initial Commercial Production
February 25, 2024 17:30 ET | 5E Advanced Materials, Inc.
Measurable progress continues towards near-term plant completion Company remains on track to commence commercial operations in CY Q2 2024 at the 5E Boron Americas Complex in California ...
Adamas1.png
Adamas One Corp. Provides Shareholder Update
February 24, 2024 23:31 ET | Adamas One Corp.
SCOTTSDALE, Ariz., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Adamas One Corp. (Nasdaq: JEWL) (“Adamas One,” “Adamas” or the “Company”), The Original Lab-Grown Diamond Company™, a high-tech company that...
Celldex Logo.jpg
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
February 24, 2024 14:05 ET | Celldex Therapeutics, Inc.
- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid...
TilrayBrands_Logo_FullColor_RBG_Horiz-01.png
Tilray Medical salue le Bundestag allemand et l’adoption historique de la loi sur le cannabis à usage médicinal en Allemagne
February 24, 2024 09:13 ET | Tilray Brands, Inc.
COLOGNE, Allemagne et NEUMÜNSTER, Allemagne, 24 févr. 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY), une société mondiale de premier plan opérant...
Alvotech_logo.jpg
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024 20:15 ET | Alvotech
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership...
Alvotech and Teva An
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024 20:15 ET | Alvotech
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S.  SIMLANDI is the first biosimilar approval under the strategic partnership...
Alvotech hlýtur mark
Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Simlandi, líftæknilyfjahliðstæðu við Humira í háum styrk
February 23, 2024 20:15 ET | Alvotech
Simlandi (AVT02) verður fyrsta líftæknilyfjahliðstæðan á markaði í Bandaríkjunum sem er útskiptanleg við Humira í háum styrkMarkaðsleyfi með útskiptanleika getur veitt einkarétt til markaðssetningar á...
Regency-Logo2012-RGB.jpg
Regency Centers Announces Whole Foods Market Anchored Development in Central Connecticut
February 23, 2024 18:44 ET | Regency Centers Corporation
CHESHIRE, Conn., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Regency Centers has acquired the land on which it plans to develop Cheshire Crossing, a 152,000-square foot shopping center anchored by Whole Foods...
logo_egain.png
eGain presenteert de nieuwe op AI gebaseerde kennistechnologie tijdens Call Centre World 2024 te Berlijn
February 23, 2024 18:37 ET | eGain Corporation
SUNNYVALE, Calif. en NEWBURY, Verenigd Koninkrijk, Feb. 24, 2024 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), het belangrijkste op AI gebaseerde kennisplatform voor klantbetrokkenheid, kondigde vandaag...